Park Ha Biological Technology Co., Ltd.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $2.5M | $2.4M | $2.5M | $1.9M |
| Cost of Revenue | $142.5K | $195.3K | $311.0K | $509.2K |
| Gross Profit | $2.4M | $2.2M | $2.1M | $1.4M |
| Gross Margin | 94.4% | 91.8% | 87.4% | 73.5% |
| Operating Expenses | ||||
| Research & Development | $238.2K | $36.7K | $30.9K | $60.7K |
| SG&A Expense | $25.5M | $814.9K | $485.0K | $707.5K |
| Operating Income | $-24.1M | $793.7K | $1.2M | $197.0K |
| Operating Margin | -956.5% | 33.3% | 48.0% | 10.3% |
| Interest Expense | — | — | — | — |
| Pretax Income | $-24.1M | $793.4K | $1.2M | $190.0K |
| Income Tax Expense | $280.6K | $314.9K | $329.5K | $-1.3K |
| Net Income | $-24.4M | $478.6K | $852.0K | $191.3K |
| Net Margin | -965.0% | 20.1% | 34.6% | 10.0% |
| EPS (Basic) | $-41.38 | $0.96 | $1.70 | $0.01 |
| EPS (Diluted) | $-41.38 | $0.96 | $1.70 | $0.01 |
| Shares Outstanding (Basic) | 588.9K | 500.0K | 500.0K | 25.0M |
| Shares Outstanding (Diluted) | 588.9K | 500.0K | 500.0K | 25.0M |
| Dividends Per Share | — | — | — | — |